Arteaus Therapeutics takes on Lilly’s migraine compound; Lilly later regains rights
- Specialty Pharmaceuticals
- R+D and Marketing-Licensing
- Reverse Licensing
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.